Trial Profile

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients - MIZAR

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nepafenac (Primary)
Indications Diabetic macular oedema; Diabetic retinopathy
Focus Registrational; Therapeutic Use
Acronyms MIZAR
Sponsors Alcon

Most Recent Events

01 Apr 2013 Status changed from recruiting to discontinued as reported by Clinical Trials Registry - India.
09 Jun 2012 Additional location Germany added as reported by European Clinical Trials Database record.
17 May 2012 Actual number of patients changed from 166 to 175 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com